KR101390625B1 - 티로신 키나제 억제제로의 처리시 세포 지방의 감소 및 심장 독성의 예측을 위한 조성물 및 방법 - Google Patents

티로신 키나제 억제제로의 처리시 세포 지방의 감소 및 심장 독성의 예측을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101390625B1
KR101390625B1 KR1020087023650A KR20087023650A KR101390625B1 KR 101390625 B1 KR101390625 B1 KR 101390625B1 KR 1020087023650 A KR1020087023650 A KR 1020087023650A KR 20087023650 A KR20087023650 A KR 20087023650A KR 101390625 B1 KR101390625 B1 KR 101390625B1
Authority
KR
South Korea
Prior art keywords
fatty acid
acid oxidation
cardiomyocytes
disorder
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087023650A
Other languages
English (en)
Korean (ko)
Other versions
KR20090008194A (ko
Inventor
사라 에스 바커스
Original Assignee
타게티드 몰레큘라 다이아그노스틱스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 filed Critical 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨
Publication of KR20090008194A publication Critical patent/KR20090008194A/ko
Application granted granted Critical
Publication of KR101390625B1 publication Critical patent/KR101390625B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
KR1020087023650A 2006-02-27 2007-02-27 티로신 키나제 억제제로의 처리시 세포 지방의 감소 및 심장 독성의 예측을 위한 조성물 및 방법 Expired - Fee Related KR101390625B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US77709606P 2006-02-27 2006-02-27
US60/777,096 2006-02-27
US82123006P 2006-08-02 2006-08-02
US60/821,230 2006-08-02
US82737206P 2006-09-28 2006-09-28
US60/827,372 2006-09-28
US82834506P 2006-10-05 2006-10-05
US60/828,345 2006-10-05
US86773606P 2006-11-29 2006-11-29
US60/867,736 2006-11-29
PCT/US2007/062871 WO2007101191A2 (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20090008194A KR20090008194A (ko) 2009-01-21
KR101390625B1 true KR101390625B1 (ko) 2014-04-29

Family

ID=38459790

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087023650A Expired - Fee Related KR101390625B1 (ko) 2006-02-27 2007-02-27 티로신 키나제 억제제로의 처리시 세포 지방의 감소 및 심장 독성의 예측을 위한 조성물 및 방법

Country Status (11)

Country Link
US (2) US8709738B2 (https=)
EP (1) EP1996939B1 (https=)
JP (2) JP5539653B2 (https=)
KR (1) KR101390625B1 (https=)
CN (2) CN101438155B (https=)
AU (1) AU2007220094B2 (https=)
CA (1) CA2643846A1 (https=)
ES (1) ES2475162T3 (https=)
IL (1) IL193715A (https=)
NZ (2) NZ594178A (https=)
WO (1) WO2007101191A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210096770A (ko) 2020-01-29 2021-08-06 한국화학연구원 심장 독성 예측 모델링 시스템 및 모델링 방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
EP3739041A1 (en) 2014-03-27 2020-11-18 The Salk Institute for Biological Studies Compositions and methods for treating type 1 and type 2 diabetes and related disorders
AU2016225076B2 (en) 2015-02-27 2018-09-13 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
AU2017269364B2 (en) 2016-05-25 2023-08-31 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
JP7032723B2 (ja) * 2017-07-21 2022-03-09 公立大学法人福島県立医科大学 薬剤の心毒性評価方法及びそのための試薬又はキット
WO2019084395A1 (en) * 2017-10-27 2019-05-02 University Of Virginia Patent Foundation COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
TWI711458B (zh) * 2019-07-08 2020-12-01 大江生醫股份有限公司 植物發酵物及其製備方法與用於胃臟保健的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
CA2459508A1 (en) * 2001-09-24 2003-04-03 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
JP4611025B2 (ja) * 2002-11-04 2011-01-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体内のブドウ糖または脂肪酸の代謝に関する高処理量測定のための重水素化ブドウ糖または脂肪の耐性試験
EP1980629A3 (en) 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Semin Oncol., vol.29, no.3(Suppl 11), pp.22-8(2002.06) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210096770A (ko) 2020-01-29 2021-08-06 한국화학연구원 심장 독성 예측 모델링 시스템 및 모델링 방법

Also Published As

Publication number Publication date
KR20090008194A (ko) 2009-01-21
CN103217520A (zh) 2013-07-24
EP1996939A2 (en) 2008-12-03
NZ594178A (en) 2013-02-22
AU2007220094B2 (en) 2013-12-05
EP1996939A4 (en) 2009-07-15
JP5539653B2 (ja) 2014-07-02
IL193715A (en) 2014-06-30
WO2007101191A2 (en) 2007-09-07
NZ571465A (en) 2011-09-30
CN101438155A (zh) 2009-05-20
EP1996939B1 (en) 2014-03-26
WO2007101191A3 (en) 2007-12-13
JP2009533017A (ja) 2009-09-17
CA2643846A1 (en) 2007-09-07
ES2475162T3 (es) 2014-07-10
US20090186910A1 (en) 2009-07-23
JP2013063090A (ja) 2013-04-11
CN101438155B (zh) 2013-04-24
US20130288285A1 (en) 2013-10-31
US8709738B2 (en) 2014-04-29
AU2007220094A1 (en) 2007-09-07
IL193715A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
KR101390625B1 (ko) 티로신 키나제 억제제로의 처리시 세포 지방의 감소 및 심장 독성의 예측을 위한 조성물 및 방법
Zhenyukh et al. High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation
Hengist et al. Mobilising vitamin D from adipose tissue: The potential impact of exercise
WO2008016730A2 (en) Compositions and methods for reducing cellular fat
Gyurko et al. Modulation of mouse cardiac function in vivo by eNOS and ANP
Reilly et al. Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3
Cartoni et al. Mitofusins 1/2 and ERRα expression are increased in human skeletal muscle after physical exercise
Aliaga et al. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells
Kitamura et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells
Hassan et al. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T
Teshigawara et al. Role of Krüppel-like factor 15 in PEPCK gene expression in the liver
Wu et al. Focal adhesion kinase mediates porcine venular hyperpermeability elicited by vascular endothelial growth factor
Baquero et al. Insulin activates epithelial sodium channel (ENaC) via phosphoinositide 3-kinase in mammalian taste receptor cells
Einstein et al. Enhanced activation of a “nutrient-sensing” pathway with age contributes to insulin resistance
Kihara et al. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells
JP4570246B2 (ja) 細胞活性を調節する方法
Huisamen et al. The impact of chronic glycogen synthase kinase-3 inhibition on remodeling of normal and pre-diabetic rat hearts
RU2570626C2 (ru) Биологический способ анализа для контроля качества нутрицевтиков и лекарственных средств
US7915255B2 (en) Metabolism-modulating agents and uses therefor
RU2345785C2 (ru) Применение рам
Kitai et al. Sensitization to hyperthermia by intracellular acidification
McCarroll et al. Dietary fat manipulation and signal transduction in ovine skin
WO2002046466A2 (en) Complexes of brca and stat polypeptides and methods of use in the detection and treatment of cancer
Gnimassou Hypoxia–and exercise-mediated effects on the muscle mass via endogenous local progenitors and the hippo signaling pathway
Eckel Glucose transport in heart: special emphasis on insulin resistance and NIDDM

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170424

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170424